Skip to main content
Premium Trial:

Request an Annual Quote

Hyseq Hires New President, COO in Preparation to Begin Clinical Trials

NEW YORK, Jan 16 – Hyseq announced Tuesday the appointment of Ted Love as president and chief operating officer, signaling the company’s plans to enter the next stage of its drug development program.

"Hyseq has focused on selecting biopharmaceutical candidates from our thousands of full length genes during the past year, with the goal of moving two candidates into clinical trials as soon as possible. Ted brings significant experience and expertise to Hyseq to take these candidates into the clinic," George Rathmann, Hyseq’s chairman and CEO, said in a statement.

While Love will replace Rathmann in the capacity of president, Rathmann will remain chairman and CEO of the company. The position of COO was newly created for Love, who will also join Hyseq's board as a director.

Previously, Love was senior vice president of development at Advanced Medicine. He also worked in clinical research, product development, and regulatory affairs at Genentech.

In the past Hyseq has formed collaborations for developing gene-based products and for commercializing the HyChip biochip.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.